Cargando…

Diagnosis and treatment of multiple myeloma and AL amyloidosis with focus on improvement of renal lesion

Multiple myeloma (MM) and AL amyloidosis are caused by the expansion of monoclonal plasma cells and secretion of dysproteinemia (Bence Jones protein and free light chain) and some patients require the hemodialysis. Myeloma kidney is mainly caused by the cast nephropathy of the distal tubuli, whereas...

Descripción completa

Detalles Bibliográficos
Autor principal:	Suzuki, Kenshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Japan 2012
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3465548/ https://www.ncbi.nlm.nih.gov/pubmed/22968855 http://dx.doi.org/10.1007/s10157-012-0684-5

Ejemplares similares

First report of CART treatment in AL amyloidosis and relapsed/refractory multiple myeloma
por: Oliver-Caldes, Aina, et al.
Publicado: (2021)

Delayed Diagnosis of Cardiac Amyloidosis Secondary to Multiple Myeloma
por: Qatanani, Ahmad, et al.
Publicado: (2021)

Nonsecretory Multiple Myeloma and AL Amyloidosis Presenting with Nephrotic Range Proteinuria
por: Beyler Kilic, Ozlem, et al.
Publicado: (2015)

Elevation of Plasmin-α2-plasmin Inhibitor Complexes in Patients with AL Amyloidosis
por: Miyazaki, Kanji, et al.
Publicado: (2018)

Diagnosis and Treatment of AL and ATTR Amyloidosis
por: Faiman, Beth, et al.
Publicado: (2021)

Pulmonary AL amyloidosis and multiple myeloma presenting as cough with diffuse pulmonary opacities
por: Xu, Alan, et al.
Publicado: (2021)

A case of multiple myeloma with AL amyloidosis showing giant Russel bodies
por: Mcphaden, Heather, et al.
Publicado: (2023)

First report of teclistamab in a patient with relapsed AL amyloidosis and multiple myeloma
por: Leung, Nelson, et al.
Publicado: (2023)

AL amyloidosis: advances in diagnosis and management
por: Koh, Youngil
Publicado: (2020)

Splenic rupture secondary to amyloid light-chain (AL) amyloidosis associated with multiple myeloma
por: Buzalewski, Jarrod, et al.
Publicado: (2019)

AL Amyloidosis in a Patient with IgD Myeloma
por: Rafik, Hicham, et al.
Publicado: (2020)

Relationship between Serum Bortezomib Concentration and Emergence of Diarrhea in Patients with Multiple Myeloma and/or AL Amyloidosis
por: Fujimoto, Yuki, et al.
Publicado: (2021)

Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis
por: Sidana, Surbhi, et al.
Publicado: (2017)

AL Amyloidosis
por: Desport, Estelle, et al.
Publicado: (2012)

A Focus on Waldenström Macroglobulinemia and AL Amyloidosis
por: Lu, Rebecca, et al.
Publicado: (2022)

Light chain (AL) amyloidosis: update on diagnosis and management
por: Rosenzweig, Michael, et al.
Publicado: (2011)

(18)F-FDG PET/CT in Primary AL Hepatic Amyloidosis Associated with Multiple Myeloma
por: Son, Youn Mi, et al.
Publicado: (2011)

Case Report: AL Amyloidosis Severe Restrictive Cardiomyopathy Associated With Multiple Myeloma—Diagnostic Difficulties
por: Kirichenko, Yulia Y., et al.
Publicado: (2022)

Bullous skin lesions in a patient with end-stage renal disease combined with myeloma and primary amyloidosis
por: Jung, Jong Hwan
Publicado: (2016)

Prevention Of Skeletal Related Events In Multiple Myeloma: Focus On The RANK-L Pathway In The Treatment Of Multiple Myeloma
por: Parrondo, Ricardo D, et al.
Publicado: (2019)

Ascites in the Course of Plasma Cell Myeloma Complicated by AL Amyloidosis
por: Debski, Jakub, et al.
Publicado: (2018)

Systemic AL Amyloidosis: Current Approaches to Diagnosis and Management
por: Fotiou, Despina, et al.
Publicado: (2020)

Oral manifestations of systemic amyloidosis, an aid to diagnosis of multiple myeloma – report of two cases
por: Dissanayaka, D.W.V.N., et al.
Publicado: (2020)

Nodular amyloidosis of the lips as a presenting feature of systemic amyloidosis associated with multiple myeloma
por: Alexanian, Claire, et al.
Publicado: (2019)

P-130: The impact of COVID-19 on the treatment regimens of myeloma and AL amyloidosis patients
por: Joyner, Katie, et al.
Publicado: (2021)

Biomarkers in AL Amyloidosis
por: Fotiou, Despina, et al.
Publicado: (2021)

AL Amyloidosis for the Cardiologist and Oncologist: Epidemiology, Diagnosis, and Management
por: Witteles, Ronald M., et al.
Publicado: (2019)

Daratumumab in the Treatment of Light-Chain (AL) Amyloidosis
por: Palladini, Giovanni, et al.
Publicado: (2021)

Congestive Heart Failure with Preserved Ejection Fraction in a Patient with Light Chain (AL) Amyloidosis and Multiple Myeloma
por: Carrizales-Sepúlveda, Edgar Francisco, et al.
Publicado: (2017)

AL Amyloidosis and Multiple Myeloma: A Complex Scenario in Which Cardiac Involvement Remains the Key Prognostic Factor
por: Ríos-Tamayo, Rafael, et al.
Publicado: (2023)

A multidisciplinary case report of multiple myeloma with renal and cardiac involvement: a look beyond amyloidosis
por: Innocenti, Samantha, et al.
Publicado: (2022)

Renal amyloidosis: a new time for a complete diagnosis
por: Feitosa, V.A., et al.
Publicado: (2022)

Light chain Amyloidosis (AL) associated with multiple myeloma revealed by peripheral bilateral polyarthritis: a case report
por: Randrianarisoa, Rova Malala Fandresena, et al.
Publicado: (2021)

Pulmonary amyloidosis as the presenting finding in a patient with multiple myeloma
por: Kronen, Ryan, et al.
Publicado: (2022)

Light Chain (AL) Amyloidosis: The Journey to Diagnosis
por: McCausland, Kristen L., et al.
Publicado: (2017)

Multifocal splenic lesions in primary AL amyloidosis secondary to amyloidosis with giant cell granulomatous reaction
por: Bhushan, Mishi, et al.
Publicado: (2020)

Diagnosis and therapy of multiple myeloma
por: Palumbo, Antonio, et al.
Publicado: (2013)

Molecular Mechanism of Pathogenesis and Treatment Strategies for AL Amyloidosis
por: Ikura, Hidehiko, et al.
Publicado: (2022)

Performance analysis of AL amyloidosis cardiac biomarker staging systems with special focus on renal failure and atrial arrhythmia
por: Dittrich, Tobias, et al.
Publicado: (2019)

Treatment Strategy for Multiple Myeloma to Improve Immunological Environment and Maintain MRD Negativity
por: Suzuki, Kazuhito, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ooh736khid78u19gpkii2ud6at